Emory University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Emory University sits in the top decile of US sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count).

1,208 total trials 208 currently recruiting 767 completed early-phase tilt top decile by trial count

Emory University: 1,208 sponsored US clinical trials, 208 recruiting.

Emory University sponsors 1,208 registered US clinical trials on ClinicalTrials.gov, 208 of them currently recruiting, and 767 completed. 170 of these trials are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 12 trials.

Top-decile sponsor footprint

Emory University ranks in the top decile of sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 47/100

767 of 926 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,208 total, page 15 of 25

COMPLETED NA

Decision Aid for Therapeutic Options In Sickle Cell Disease

NCT02326597

COMPLETED Phase 1

BMT Autologous MSCs for GvHD

NCT02359929

TERMINATED NA

Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women

NCT02333045

COMPLETED

Reliability of Sensor Spacing for NIRS in Traumatic Tibia Fractures

NCT02301832

COMPLETED NA

Legume Diet Satiety Pilot Study

NCT02269631

COMPLETED NA

Development of a Manual-based, Interdisciplinary Intervention for Youth With ASD and Obesity

NCT02328638

TERMINATED Phase 1

Ganetespib Window of Opportunity Study in Head and Neck Cancers

NCT02334319

TERMINATED Phase 2

Phase II Study of Everolimus Beyond Progression

NCT02269670

COMPLETED NA

Distance Savvy: Testing Tele-Savvy, a Distance Dementia Family Caregiver Education Program

NCT02300584

COMPLETED NA

Redox Imbalance and the Development of Cystic Fibrosis Diabetes

NCT02202876

COMPLETED NA

A Mobile Personal Health Record for Behavioral Health Homes

NCT01890226

COMPLETED NA

Community Pediatric Acceptability Study (CPAS)

NCT02610699

COMPLETED Phase 2

Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

NCT02343224

TERMINATED Phase 2

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

NCT02273752

TERMINATED

Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a Database

NCT02309333

TERMINATED Phase 4

Post-operative Pain Control After Pediatric Adenotonsillectomy

NCT02296840

COMPLETED NA

Researching Alveolar Macrophage Improvements With Supplements in HIV

NCT02264860

COMPLETED NA

Reducing Perinatal Anal Incontinence Through Early Pelvic Floor Muscle Training: a Prospective Pilot Study

NCT02270008

COMPLETED

NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients

NCT04548596

COMPLETED

BioEnergetics and Metabolomics in Cystic Fibrosis

NCT02225899

COMPLETED Phase 4

The ISLAND Study: InSuLa Assessed Needs for Depression

NCT02137369

COMPLETED Phase 2

Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)

NCT02147067

COMPLETED NA

iChoose Decision Kidney Aid for End-Stage Renal Disease Patients

NCT02235571

COMPLETED Phase 2

CAndesartan vs LIsinopril Effects on the BRain

NCT01984164

COMPLETED Phase 4

Liposomal Bupivacaine for Pain Control Following Anterior Cruciate Ligament Reconstruction

NCT02189317

COMPLETED Phase 1

Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors

NCT02257476

COMPLETED NA

Online CBT-I for High Blood Pressure

NCT02299193

COMPLETED NA

Video-Based Treatment Options for Basal Cell Carcinoma

NCT02158650

COMPLETED NA

Improving Consent and Survey Procedures for Young MSM in Web-based HIV Prevention

NCT02139566

COMPLETED NA

Planning for SUCCESS

NCT02185742

COMPLETED NA

Patient Centered Comprehensive Medication Adherence Management System in Patients With Sickle Cell Disease

NCT02371720

COMPLETED NA

Living Well Project for Persons With AIDS

NCT01848483

COMPLETED NA

Improving Patient Education for Lymphoma and Leukemia Inpatients

NCT02642510

COMPLETED NA

Stimulus-Stimulus Pairing Study

NCT02464527

COMPLETED NA

CBCT for Parents of Children With Autism

NCT02574559

COMPLETED NA

Music for Health Project

NCT01786148

TERMINATED Phase 2

PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)

NCT02074436

COMPLETED Phase 3

Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome

NCT02132195

COMPLETED NA

Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels

NCT02098876

COMPLETED Phase 1

Meditation for Emotional Numbing in Post-Traumatic Stress Disorder

NCT02163941

COMPLETED Phase 4

Propranolol and Botulinum Toxin for Essential Vocal Tremor

NCT02111369

COMPLETED Phase 4

ADA Linagliptin in Long Term Care

NCT02061969

COMPLETED NA

Systems Biology of PNEUMOVAX®23 and PREVNAR 13®

NCT01307449

COMPLETED NA

Cast vs. Splints for Minimally Displaced Distal Radius Fractures in the Elderly

NCT02066857

COMPLETED

Comparison of Gabapentin and Pregabalin for Radicular Pain

NCT02064790

COMPLETED

Mucosal Versus Fecal Microbiota in FMT

NCT02133651

COMPLETED

RF Lesion Monitoring With 8mm IntellaTip MiFi XP

NCT02089672

TERMINATED Phase 4

Accelerated Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging

NCT02114697

COMPLETED NA

rTMS in Treatment Resistant Depression

NCT02080507

COMPLETED Phase 4

Liraglutide Hospital Discharge Trial

NCT01919489

← Previous Page 15 of 25 Next →

Phase Distribution

PhaseTrial count
Phase 1 154
Phase 2 190
Phase 3 36
Phase 4 134

What is open in the Emory University pipeline

208 recruiting of 1,208 indexed (17% open); 767 completed (63%).

Phase mix: 170 late (III/IV) vs 344 early (I/II) (early-phase heavy).

Top condition: Depression (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Emory University: open-pipeline peers nationwide

Peers matched on 1,208 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 12%14%16%18%20% Total trials Recruiting share Emory UniversityNorthwestern UniversityUniversity of PittsburghNYU Langone HealthUniversity of Alabama at BirminghamBaylor Research InstituteNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Hunter College of City University of New YorkOchsner Health System
Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,208 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this Emory University page

1,208 registered trials is a research-attention snapshot, not an endorsement of Emory University or any single study.

  • 208 of Emory University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition Emory University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Emory University pipeline card: 1,208 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.